WINSTON-SALEM, N.C., Nov. 2 /PRNewswire-FirstCall/ -- Targacept, Inc. , today announced that the company will conduct a conference call and an audio webcast at 5:00 p.m. ET on Thursday, November 9, 2006 following the after-market release of its unaudited financial results for the third quarter ended September 30, 2006. J. Donald deBethizy, Ph.D., President and Chief Executive Officer, and Alan A. Musso, Vice President and Chief Financial Officer, will host the call to discuss the company’s third quarter financial results and to provide an update on the company’s product development programs and business activities.
(Logo: http://www.newscom.com/cgi-bin/prnh/20010517/CHTH002LOGO )
A live webcast of the conference call will be accessible from the Investor Relations page of Targacept’s website, www.targacept.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will also be available on Targacept’s website for at least two weeks following the call.
The conference call may be accessed by dialing 866-510-0704 for domestic participants and 617-597-5362 for international callers (reference passcode 44122177). A replay of the conference call may be accessed through November 23, 2006 by dialing 888-286-8010 for domestic callers and 617-801-6888 for international callers (reference passcode 53769085).
About Targacept
Targacept is a clinical-stage biopharmaceutical company that discovers and develops NNR Therapeutics(TM), a new class of drugs for the treatment of central nervous system diseases and disorders. Targacept’s product candidates selectively modulate neuronal nicotinic receptors that serve as key regulators of the nervous system to promote therapeutic effects and limit adverse side effects. Targacept has product candidates in development for Alzheimer’s disease and cognitive deficits in schizophrenia, pain and depression and multiple preclinical programs. Targacept is located in Winston-Salem, North Carolina.
Forward-Looking Statements
Any statements in this press release about expectations, plans and prospects for Targacept, Inc. and all other statements that are not purely historical in nature constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “promise,” “continue,” “ongoing” and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those expressed or implied by forward- looking statements as a result of various important factors, including those described under the heading “Risk Factors” in our most recent Quarterly Report on Form 10-Q and in other filings that we make with the Securities and Exchange Commission. As a result of the risks and uncertainties, the results or events indicated by the forward-looking statements may not occur. We caution you not to place undue reliance on any forward-looking statement.
In addition, any forward-looking statements in this release represent our views only as of the date of this release and should not be relied upon as representing our views as of any subsequent date. We anticipate that subsequent events and developments may cause our views to change. Although we may elect to update these forward-looking statements publicly at some point in the future, whether as a result of new information, future events or otherwise, we specifically disclaim any obligation to do so, except as required by applicable law.
Photo: http://www.newscom.com/cgi-bin/prnh/20010517/CHTH002LOGOPRN Photo Desk, photodesk@prnewswire.comTargacept, Inc.
CONTACT: Alan Musso, VP and CFO of Targacept, Inc., +1-336-480-2186, oralan.musso@targacept.com; or Michelle Linn of Linnden Communications,+1-508-419-1555, or linnmich@comcast.net, for Targacept, Inc.
Web site: http://www.targacept.com//
